Development Pipeline

Our novel, biomarker-driven product pipeline addresses distinct molecular targets and biologic pathways, including immunotherapies and tumor-cell targeted product candidates, that are relevant across a variety of cancers.

Development Pipeline

Our biomarker-driven product pipeline addresses distinct molecular targets and biologic pathways that are relevant across a variety of cancers.

Ikena is leveraging its core capabilities in oncology drug discovery, translational sciences and clinical development to build a next generation product pipeline that addresses a broad range of cancers. By targeting defined subgroups of patients based on their biomarker profiles, we are methodically building a growing pipeline of unique patient-directed therapies: bringing the right drug to the right patient. Our lead product candidate IK-007 is currently in clinical development for the treatment of microsatellite stable colorectal cancer and PD-1/L1 refractory non-small cell lung cancer.
Program
Indication
  • Disc.
  • Pre-Cli.
  • Ph1
  • Ph2
IK-007 + Pembrolizumab1 IK-007 + Pembro.1
MSS Colorectal Cancer
MSS Colorectal Cancer
  • PH1
IK-007 + Pembrolizumab1 IK-007 + Pembro.1
PD-1/L1 Refractory NSCLC
PD-1/L1 Refractory NSCLC
  • PH1
IK-175 IK-175
AHR-activated Cancers
AHR-activated Cancers
  • PH1
BMS Collaboration2
IK-412 IK-412
Undisclosed
Undisclosed
  • Pre-C
BMS Collaboration2
Hippo Pathway Drug Candidate Hippo Pathway Drug
Nf2 and LATS-mutated cancers
Nf2 and LATS-mutated cancers
  • Disc.
Undisclosed Undisclosed
Undisclosed
Undisclosed
  • Disc.

Explore the scientific research that supports our pipeline.